Skip to content

Olink® Proteomics

Protein biomarkers, along with other omics markers, can be used to predict response, stratify patient populations, and provide insights into disease biology.
Olink® offers a high-throughput solution for protein biomarker discovery with thoroughly validated assays that provide exceptional specificity at high-multiplex levels. Widely used in clinical biomarker research, Olink can be applied across all stages of drug development, from early discovery through preclinical and clinical development to postapproval activities such as postmarket surveillance and label expansion. 

Precision customizes our Olink services to meet your specific study objectives

Our Precision team will work with you to discuss proteomic biomarker needs for clinical trials, for example to help you investigate the mechanism of action of your new therapeutic or narrow down your list of potential clinical biomarkers to meet your endpoints. Below is a selection of some of the ways in which we can utilize Olink for your projects.

Drug Target Identification

  • Identify protein quantitative trait loci (pQTLs) to link genetic variation, proteins, and disease

  • Gain insight into tumor biology, mechanism of immune modulation, phenotype changes, transformation of cold to hot tumors

Biomarker Analysis & Screening

  • Analyze longitudinal biomarker data between early and later timepoints to identify key biomarkers associated with drug-sensitive to drug-resistant state transitions

Protein Response Validation in Clinical Trials

  • Predict and monitor treatment response, treatment sensitivity, and mechanism of immune resistance

  • Guide strategy to optimize response rates and identify novel targetable pathways

Exploratory Endpoints in Clinical Trials

  • Examine the association of circulating protein biomarkers with clinical outcomes

  • Predict onset and mechanism of treatment-associated toxicity, monitoring cytokine release syndrome and neurotoxicity

  • Predict recurrence and on-treatment progression in adjuvant settings


How does Olink work?

Olink’s Proximity Extension Assay (PEA) uses 2 matched antibodies per target antigen. Each antibody pair is labeled with unique DNA oligo barcodes. When the antibodies bind to the same target protein in solution, the DNA oligo strands anneal with enough stability to enable DNA extension. The DNA barcode is then amplified, and the resulting amplicons are measured by qPCR or next-generation sequencing for absolute or relative quantification.

The integration of the Olink Signature Q100 instrument allows for the high-multiplex technique of the quantification of protein biomarkers with

  • Minimal clinical sample volume (as low as 1 µL of plasma/serum)
  • Exceptional sensitivity and specificity
  • Coverage of a broad dynamic range
  • A wide range of accepted biologic sample types

Olink panels scale from midplex Olink Target 48 and Olink Target 96 down to customized Olink Focus and Olink Flex.

Olink’s prevalidated and custom panels

Olink Target 96Olink Target 48Olink FlexOlink Focus
Choose from 15 thoughtfully designed panels and measure up to 92 proteins per panel.

Examples of Target 96 Panels : Cardiovascular II & III, Oncology, Cardiometabolic, Neurology, Cell Regulation Inflammation, Immuno-oncology, Metabolism
Target 48 cytokine panel measures 45 carefully selected inflammatory proteins. Customizable made-to-order panel enables the selection and combination of up to 21 human proteins. Mix and match from ~200 thoroughly prevalidated protein biomarkers. Customized panels for specific and exclusive studies are designed and optimized together with Link. Select up to 21 proteins from Olink’s full assay library

Additional cytokine and protein profiling services

  • MSD

    Measuring a range of analytes in complex sample matrices consistently and at high sensitivity, with applications including ADA, NAb, TAb, and PK assays
  • Quanterix SIMOA®

    Precise quantification of analytes in multiple matrices at sensitivity down to femtomolar (fM) levels, enabling analysis of analytes that may have been previously undetectable

  • Western blotting

    Providing western blotting via automated platforms to ensure accurate, reproducible results